
A. In vivo therapeutic efficacy study
Sample collection and treatment:
Subjects enrolled on D0, administered CQ (N = 125)
Withdraws (n = 5);
Loss to follow up (n = 13)
Completed 28-day follow up, administered PQ (n = 107)
Pv+ on D0 only (n = 74, 74 isolates)
Pv+ on D0, 2 only (n = 15, 30 isolates)
Pv+ on D0, 2, 7 only (n = 1, 2 isolates)
Pv+ on D0, 2, 7, Rec (n = 1, 3 isolates)
PQ completed (n = 1)
Pv+ on D0, 2, Rec (n = 2, 6 isolates)
PQ completed (n = 2)
Pv+ D0 and Rec (n = 14, 28 isolates)
PQ completed (n = 7)
PQ not completed (n = 7)
Genotype processing:
Selected for genotyping (D0, n = 33; D2, n = 19; DRec, n = 17)
Pvmdr1 sequencing (n = 69)
Failed to amplify (D2, n = 19; DRec, n = 2)
958M/Y976/1076L (D0, n = 33; DRec, n = 14)
958M/Y976/F1076 (DRec, n = 1)
MS fragment analysis (n = 50)
Failed to amplify (D2, n = 19)
Full allelic haplotypes (D0, n = 33; DRec, n = 17)
B. In vitro drug assay
Sample collection and treatment:
Subjects enrolled, , administered CQ (N = 96)
Isolates excluded due to time delay in processing (n = 15)
Isolates processed (n = 81)
Invalid IC50 results (n = 13)
Valid IC50 results (n = 68)
Genotype processing:
Selected for genotyping (n = 20)
Pvmdr1 sequencing (n = 20)
Failed to amplify (n = 2)
958M/Y976/1076L (n = 17)
958M/Y976/F1076 (n = 1)
MS fragment analysis (n = 20)
Full allelic haplotypes (n = 20)